Search: onr:"swepub:oai:DiVA.org:uu-472390" >
AIM-AF :
AIM-AF : A Physician Survey in the United States and Europe
-
- Camm, A. John (author)
- St Georges Univ, London, England.
-
- Blomström-Lundqvist, Carina (author)
- Uppsala universitet,Kardiologi-arrytmi
-
- Boriani, Giuseppe (author)
- Univ Modena & Reggio Emilia, Modena, Italy.
-
show more...
-
- Goette, Andreas (author)
- St Vincenz Hosp Paderbom, Dept Cardiol & Intens Care Med, Paderborn, Germany.
-
- Kowey, Peter R. (author)
- Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA.;Lankenau Heart Inst, Philadelphia, PA USA.
-
- Merino, Jose L. (author)
- Univ Autonoma Madrid, La Paz Univ Hosp, Idipaz, Madrid, Spain.
-
- Piccini, Jonathan P. (author)
- Duke Univ, Duke Clin Res Inst, Durham, NC USA.
-
- Saksena, Sanjeev (author)
- Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA.
-
- Reiffel, James A. (author)
- Columbia Univ, New York, NY USA.
-
show less...
-
St Georges Univ, London, England Kardiologi-arrytmi (creator_code:org_t)
- Ovid Technologies (Wolters Kluwer Health), 2022
- 2022
- English.
-
In: Journal of the American Heart Association. - : Ovid Technologies (Wolters Kluwer Health). - 2047-9980. ; 11:6
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: Guideline recommendations are the accepted reference for selection of therapies for rhythm control of atrial fibrillation (AF). This study was designed to understand physicians' treatment practices and adherence to guidelines.Methods and Results: The AIM-AF (Antiarrhythmic Medication for Atrial Fibrillation) study was an online survey of clinical cardiologists and electrophysiologists that was conducted in the United States and Europe (N=629). Respondents actively treated >= 30 patients with AF who received drug therapy, and had received or were referred for ablation every 3 months. The survey comprised 96 questions on physician demographics, AF types, and treatment practices. Overall, 54% of respondents considered guidelines to be the most important nonpatient factor influencing treatment choice. Across most queried comorbidities, amiodarone was selected by 60% to 80% of respondents. Other nonadherent usage included sotalol by 21% in patients with renal impairment; dofetilide initiation (16%, United States only) outside of hospital; class Ic agents by 6% in coronary artery disease; and dronedarone by 8% in patients with heart failure with reduced ejection fraction. Additionally, rhythm control strategies were frequently chosen in asymptomatic AF (antiarrhythmic drugs [AADs], 35%; ablation, 8%) and subclinical AF (AADs, 38%; ablation, 13%). Despite guideline algorithms emphasizing safety first, efficacy (48%) was selected as the most important consideration for AAD choice, followed by safety (34%).Conclusions: Despite surveyed clinicians recognizing the importance of guidelines, nonadherence was frequently observed. While deviation may be reasonable in selected patients, in general, nonadherence has the potential to compromise patient safety. These findings highlight an underappreciation of the safe use of AADs, emphasizing the need for interventions to support optimal AAD selection.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- atrial fibrillation
- antiarrhythmic drug
- physician
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database